Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 55

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 55
---
 retention over the long-term. Accordingly, the Compensation Committee determined not to make any significant changes to our executive compensation policies or decisions as a result of the vote; however, our Compensation Committee determined to monitor and continually evaluate our compensation program going forward in light of our stockholders’ views and our transforming business needs. Our Compensation Committee expects to continue to consider the outcome of our “say on pay” votes and our stockholders’ views when making future compensation decisions for our named executive officers. For additional information regarding our stockholder outreach and engagement efforts, see “Our Approach to Stockholder Engagement” above. Elements of Our 2024 Executive Compensation Program Base Salaries The base salaries of our named executive officers are an important part of their total compensation package, and are intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent. In February 2024, upon the recommendation of our Compensation Committee, our Board reviewed the base salaries of our named executive officers and approved increases to base salaries in amounts ranging from approximately 3% to 8% for each of our named executive officers. Based on our Compensation Committee’s subjective judgement, our Compensation Committee determined these increases were appropriate in light of each executive’s individual performance and peer data. The 2024 base salaries of our named executive officers are reflected below.

| Named Executive Officer | ​ | ​ | 2023 BaseSalary |   |         |   | ​ | ​ | 2024 BaseSalary |   |         |   | ​ | ​ | PercentageIncreasefrom 2023Base Salary | ​ |
|:------------------------|:--|:--|:----------------|:--|--------:|:--|:--|:--|:----------------|:--|--------:|:--|:--|:--|:---------------------------------------|:--|
| Jasbir Seehra, Ph.D.    | ​ | ​ | ​               | $ | 650,000 | ​ | ​ | ​ | ​               | $ | 700,000 | ​ | ​ | ​ | 8%                                     | ​ |
| Keith Regnante          | ​ | ​ | ​               | $ | 435,000 | ​ | ​ | ​ | ​               | $ | 448,050 | ​ | ​ | ​ | 3%                                     | ​ |
| Yung Chyung, M.D